The primary objective of this study is to provide expanded access to and characterize the safety profile of AMG 510 (sotorasib) in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.
Drug: AMG 510
Administered as an oral tablet.
Other Name: Sotorasib
Inclusion Criteria - Age ≥ 18 years - Ineligibility for participation in any ongoing clinical study of the investigational product - Pathologically documented, locally-advanced and unresectable or metastatic Non Small Cell Lung Cancer (NSCLC) with KRAS p.G12C mutation confirmed through molecular testing - Exhausted other standard of care options for locally advanced and unresectable or metastatic disease including platinum-based combination chemotherapy and PD 1/PD-L1 immunotherapy (unless contraindicated) - Performance Status ≤ 2
Exclusion Criteria - Active Brain Metastases - Active hepatitis B or hepatitis C virus - Current active malignancy other than NSCLC - Participants previously enrolled in sotorasib Study 20190009 (CodeBreaK 200)
Amgen Call Center